Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment

Leukemia

Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers

Am J Hematol

Abaza Y, Winer ES, Murthy GSG, Shallis RM, Matthews AH, Badar T, Geramita EM, Kota VK, Swaroop A, Doukas P, Bradshaw D, Helenowski IB, Liu Y, Zhang H, Im A, Litzow MR, Perl AE, Atallah E, Altman JK

doi: 10.1002/ajh.27231

Leukemia

Genetic Risk Stratification and Outcomes Among Treatment-Naive Patients With AML Treated With Venetoclax and Azacitidine

Blood

Döhner H, Pratz KW, DiNardo CD, Wei AH, Jonas BA, Pullarkat V, Thirman MJ, Récher C, Schuh AC, Babu S, Li X, Ku G, Liu Z, Sun Y, Potluri J, Dail M, Chyla B, Pollyea DA

doi: 10.1182/blood.2024024944

Leukemia

A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents

Leukemia

Shahswar R, Gabdoulline R, Krueger K, Wichmann M, Götze KS, Braitsch K, Meggendorfer M, Schmalbrock L, Bullinger L, Modemann F, Fiedler W, Krauter J, Kaun S, Rotermund S, Voß A, Behrens YL, Bergmann AK, Koller E, Beutel G, Thol F, Heidel F, Heuser M

doi: 10.1038/s41375-024-02501-6

Leukemia

Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic Designation

Am J Hematol

Senapati J, Kantarjian HM, Haddad FG, Short NJ, Borthakur G, Kanagal-Shamanna R, Tang G, Jabbour E, DiNardo CD, Daver N, Montalban-Bravo G, Shah V, Alousi A, Shpall E, Popat U, Garcia-Manero G, Ravandi F, Kadia TM

doi: 10.1002/ajh.27561

Leukemia

Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance

Haematologica

Sobas MA, Turki AT, Ramiro AV, Sánchez AH, Elicegui JM, González T, Melchor RA, Abáigar M, Tur L, Dall'Olio D, Sträng E, Tettero JM, Castellani G, Benner A, Döhner K, Thiede C, Metzeler KH, Haferlach T, Damm F, Ayala R, Martínez-López J, Mills KI, Sierra J, Lehmann S, Porta MGD, Mayer J, Reinhardt D, Medina RV, Schulze-Rath R, Barbus M, Hernández-Rivas JM, Huntly BJP, Ossenkoppele G, Döhner H, Bullinger L

doi: 10.3324/haematol.2024.285805

Leukemia

Improvements in Posttransplant Outcomes Over Two Decades in Older Patients with Acute Myeloid Leukemia in the EBMT ALWP Study

Clin Cancer Res

Bazarbachi A, Labopin M, Moukalled N, Kröger N, Rautenberg C, Schetelig J, Finke J, Blau IW, Blaise D, Stelljes M, Eder M, Platzbecker U, Dreger P, Bethge W, Tischer J, Burns D, Sengeloev H, Brissot E, Giebel S, Nagler A, Ciceri F, Mohty M

doi: 10.1158/1078-0432.CCR-23-3673

Leukemia

Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients

Blood Cancer J

Schmälter AK, Ngoya M, Galimard JE, Bazarbachi A, Finke J, Kröger N, Bornhäuser M, Stelljes M, Stölzel F, Tischer J, Schroeder T, Dreger P, Blau IW, Savani B, Giebel S, Esteve J, Nagler A, Schmid C, Ciceri F, Mohty M

doi: 10.1038/s41408-024-01060-4

Leukemia

Peripheral blood stem cell versus bone marrow graft for patients ≥60 years undergoing reduced intensity conditioning haploidentical transplantation for acute myeloid leukemia in complete remission: An analysis of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Am J Hematol

Devillier R, Galimard JE, Blaise D, Raiola AM, Bramanti S, Grillo G, Pastano R, de Latour RP, Busca A, López-Corral L, Rodríguez AB, Schmid C, Forcade E, Vydra J, Solano C, Bug G, Neubauer A, Charbonnier A, Brissot E, Nagler A, Ciceri F, Mohty M

doi: 10.1002/ajh.27343

Leukemia

Comparable relapse incidence after unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide versus conventional anti-graft versus host disease prophylaxis in patients with acute myeloid leukemia: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Am J Hematol

Nagler A, Ngoya M, Galimard JE, Labopin M, Blau IW, Kröger N, Gedde-Dahl T, Schroeder T, Burns D, Salmenniemi U, Rambaldi A, Choi G, Peffault de Latour R, Vydra J, Sengeloev H, Eder M, Mielke S, Forcade E, Kulagin A, Ciceri F, Mohty M

doi: 10.1002/ajh.27383

Related content

Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers

Genetic Risk Stratification and Outcomes Among Treatment-Naive Patients With AML Treated With Venetoclax and Azacitidine

A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents

Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic Designation

Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance

Improvements in Posttransplant Outcomes Over Two Decades in Older Patients with Acute Myeloid Leukemia in the EBMT ALWP Study

Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients